Rhythm Pharmaceuticals Inc (RYTM) Stock Analysis

Rhythm Pharmaceuticals Inc (RYTM) is a publicly traded company in the HEALTHCARE sector. It trades at $84.35, carries a market capitalization of $6.03B. This page summarizes the public market data, fundamentals, and frequently asked questions for RYTM, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Rhythm Pharmaceuticals Inc currently has a Bullish sentiment score of 0.37.

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc. is a Boston-based biopharmaceutical company at the forefront of developing innovative therapies for rare genetic obesity disorders. Its flagship product, Imcivree (setmelanotide), uniquely addresses the biological mechanisms underlying severe obesity linked to specific genetic conditions, thereby offering transformative treatment options for underserved patient populations. With a strong foundation in melanocortin system research, Rhythm is strategically expanding...

GNG Research Analysis

GNG Research scores Rhythm Pharmaceuticals Inc (RYTM) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for RYTM.

Frequently Asked Questions

Does RYTM pay dividends?

Rhythm Pharmaceuticals Inc (RYTM) does not currently pay a regular dividend.

What is RYTM's market cap?

Rhythm Pharmaceuticals Inc (RYTM) has a market capitalization of $6.03B with a current stock price of $84.35.